Key facts
- It has raised $30K; the latest was Angel (individual) ($30K) in Nov 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Milestone Gyno-mics
- ·The full record, as it builds
Funding rounds
No funding rounds for Milestone Gyno-mics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Milestone Gyno-mics
Developer of a non-invasive AI-driven diagnostic test designed for the early detection and assessment of endometriosis. The company uses a molecular, non-invasive diagnostic blood test to analyze genetic, immune, and microbial signals, enabling clinicians and patients to treat pain, reverse infertility, and improve long-term outcomes.
- Sector
- Healthcare
- HQ
- Cupertino, CA, United States
- Founded
- 2025
- Website
- milestonegx.com/
- Ownership
- Privately Held (backing)
Milestone Gyno-mics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Milestone Gyno-mics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Milestone Gyno-mics in its N-PORT filings yet. We sweep new filings monthly.